Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Glioblastoma 9Central Nervous System Neoplasms 6Brain Neoplasms 6Oligodendroglioma 3Gliosarcoma 3Astrocytoma 3Sarcoma 2Optic Nerve Glioma 2Neoplasm Metastasis 2Glioma 2Ependymoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Vipoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Prolactinoma 1Pituitary Neoplasms 1Pheochromocytoma 1Ovarian Neoplasms 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia Type 2b 1

Interventions

veliparib 1Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Zollinger-Ellison Syndrome × Temozolomide × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡